Get the Stockscreener App
102.30
0.55%
-0.57
After Hours:
102.50
0.20
+0.20%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $102.30, with a volume of 7.12M.
It is down -0.55% in the last 24 hours and down -6.63% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$102.87
Open:
$102.51
24h Volume:
7.12M
Relative Volume:
0.65
Market Cap:
$177.76B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
27.52
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
+0.41%
1M Performance:
-6.63%
6M Performance:
-23.51%
1Y Performance:
-17.79%
1-Day Range:
$101.85
$103.08
1-Week Range:
$100.88
$103.79
52-Week Range:
$100.88
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
102.30 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.30 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.19 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Evercore ISI Lowers Price Target for Abbott Laboratories (ABT) t - GuruFocus
Medical Foods Market Is Going to Boom |• Abbott • Danone - openPR.com
Rathbones Group PLC Increases Position in Abbott Laboratories $ABT - MarketBeat
Abbott’s Lisa Earnhardt to deliver DeviceTalks Minnesota keynote - MassDevice
Abbott Laboratories $ABT Holdings Reduced by Cidel Asset Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC - MarketBeat
Abbott India Ltd stock: What you need to know for smart investing now - AD HOC NEWS
NovaPoint Capital LLC Raises Position in Abbott Laboratories (NYSE:ABT) - 富途牛牛
The Best Dividend ETF to Buy in April 2026 If You Want Passive Income - The Motley Fool
Abbott Laboratories Embarks on a Transformative $23 Billion Acquisition - AD HOC NEWS
ABT SEC FilingsAbbott Labs 10-K, 10-Q, 8-K Forms - Stock Titan
Abbott launches nationwide campaign on National Vitamin C Day to highlight role of micronutrient in wellness - MediaNews4U
A Dividend Dynasty: Abbott Laboratories' Enduring Payout Streak - AD HOC NEWS
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - AD HOC NEWS
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT) - The Globe and Mail
Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target - TIKR.com
Abbott Laboratories (ABT) latest stock news and headlines - Yahoo Finance Singapore
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott India Ltd Stock: A Stable Player in India's Booming Healthcare Sector for Long-Term Investors - AD HOC NEWS
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders - simplywall.st
Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan
Director at Abbott (NYSE: ABT) receives stock equivalent unit award - Stock Titan
Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan
Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan
Abbott Laboratories (ABT) director Nita Ahuja granted 102 stock equivalent units - Stock Titan
Sinocare Can't Scrap Abbott's Glucose Monitor Ban At UPC - Law360
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT - MarketBeat
What's Driving Abbott Labs Today - Yahoo
Abbott India Ltd Stock: Steady Growth in India's Pharmaceutical Sector Amid Evolving Healthcare Dema - AD HOC NEWS
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT - MarketBeat
Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT - MarketBeat
Drug Delivery Device Market Is Booming Worldwide 2026-2033 | - openPR.com
Abbott Laboratories Expands into Wearable Technology Through Whoop Investment - AD HOC NEWS
Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar - finance.yahoo.com
Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes - MSN
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration - simplywall.st
Abbott Laboratories completed the acquisition of North Island Assets of Synlait Milk from Synlait Milk Limited. - MarketScreener
Abbott joins $575M funding round for wearable maker Whoop - MassDevice
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) (NYSE:ABT) - seekingalpha.com
Best Healthcare Stocks to Buy Right Now for Long-Term Growth - The Motley Fool
Reasons to Retain Abbott Stock in Your Portfolio Now - TradingView
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - finance.yahoo.com
20,751 Shares in Abbott Laboratories $ABT Bought by Shrier Wealth Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Abbott Laboratories Pakistan : Change in Date and Time of the 77th Annual General Meeting - MarketScreener
List of 29 Acquisitions by Abbott (Apr 2026) - Tracxn
Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors - Cardiovascular Business
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story - simplywall.st
Whoop raises $575M, adds Abbott as strategic investor - medtechdive.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):